Robert J. Anderson, MD
Robert J. Anderson, MD

Robert J. Anderson, MD

Professor
School of Medicine

Academic Appointments

Department

  • Medicine

Position

  • Professor

Education

  • Minnesota,M.S.,79-81
  • Northwestern University Medical School,M.D.,69-73

Publications and Presentations

Articles

  • Mark Henry Joven and Robert J. Anderson (2016) Pneumocystis jirovecii Pneumonia Associated with Systemic Glucocorticoids in the Treatment of Type 2 Amiodarone-Induced Thyrotoxicosis. AACE Clinical Case Reports: Winter 2016, Vol. 2, No. 1, pp. e46-e49., AACE Clinical Case Report, 2016, Vol. 2, No. 1, e46-e49, 2016
  • Joven, M., Anderson, R.J.:White Knight. Consultant 360. In Press, August 2015, Consultant 360, 2015 55(8), 666-668, 2015
  • Shah, K, Zena, M, Adickes, E, and Anderson, RJ: Case of concurrent MTC and PTC in a patient with a germline RET mutation. Endocrine Pathology. In Press July 10, 2015., Endocrine Pathology, 2015 (26), 279-283, 2015
  • Joven MH, Anderson RJ. Update on blood pressure control and renal outcomes in diabetes mellitus. Curr Diab Rep. 2015 Jul;15(7):613. doi: 10.1007/s11892-015-0613-6. PMID: 25990743, Current Diabetes Reports, 2015 Jul;15(7), 613, 2015
  • Hayward, R., Reaven, P., Wiitala, W., Bahn, G., Reda, R., Ge, L., McCarren, M., Duckworth, W., and Emanuele, N., for the VADT Investigators (includes Anderson, RJ, Site Principal Investigator). Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015 June;372(23):2197-2206. doi: 10.1056/NEJMoa1414266., New England Journal of Medicine, 2015 June;372(23), 2197-2206, 2015
  • Leiter L, Teah H, Braunwald E, et al. for the SVAOR-TIMI 53 Steering Committee and Investigators (includes Anderson, RJ as Site PI). Efficacy and safety of Saxigliptin in older participants in the SAVOR-TIMI 53 Trial. Diabetes Care 2015;1145-1153 / DOI: 10.2337/dc14-2868., Diabetes Care, 2015 June 38(6), 1145-1153, 2015
  • Saremi A, Schwenke DC, Bahn G, Ge L, Emanuele N, Reaven PD; VADT Investigators (includes R.J. Anderson as site PI). The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial (VADT). Metabolism . 2015 Feb;64(2):218-25. doi: 10.1016/j.metabol.2014.10.010. Epub 2014 Oct 17., Metabolism, 2015 Feb;64(2), 218-25, 2015
  • Joven, M.H., Hutfless, G.S., Anderson, R.J.: Follicular Thyroid Cancer with Pulmonary Metastasis Presenting as Toxic Autonomously Functioning Thyroid Nodule. AACE Clinical Case Reports vol 1:e1-e4, DOI:10.4158/EP14384.CR, January, 2015., AACE Clinical Case Report, Vol 1, e1-e4, 2015
  • Shah, K.K., Tarasova, V.D., Davidian, M., Anderson, R.J.: Painful Acute Radiation Thyroiditis Induced By 131I Treatment of Graves’ Disease. BMJ Case Reports. [Published online 1/9/2015] doi:10.1136/bcr-2014-207670 (PMID: 25576511)., BMJ Case Report, OnLine, 2015
  • Tarasova, V.D., Nahar, N.N., Dietz, N., Recker, R.R., Anderson, R.J.: Unique Occurrence and Course in a Patient with PTEN Hamartoma Tumor Syndrome and Graves’ Disease. Letters to the Editor, Endocr Pract 20 (No.12) 1-2, December, 2014., Endocrine Practice, Vol. 20, No. 12, 1354-1356, 2014
  • Joven M.H. and Anderson, R.J.: Marine-Lenhart Syndrome Endocrine 2014, September; DOI 10.1007/s12020-014-0412-x (PMID: 25205447)., Endocrine, 2015 Jun;49(2), 570-1, 2014
  • Anderson, R.J., Bahn, G., Emanuele, N. Marks, J., Duckworth, W. for the VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2014. http://care.diabetesjournals.org/content/early/2014/07/16/dc14-0284. Published online July 21, 2014. Diabetes Care 37:2782-2788, 2014. (PMID: 25048382)., Diabetes Care, July 21, 2014, OnLine, 2014
  • Drincic, A. and Anderson, R.J.: Adrenal Hirsutism/Virilization, Adrenal Section for the American College of Endocrinology Self Assessment Program (ASAP-online) 2014. Available at: https://education.aace.com., American College of Endocrinology Self Assessment Program, OnLine, 2014
  • Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, Reaven P; VADT Study Group (includes R.J. Anderson as site PI). Association of Blood Glucose Control and Pancreatic Reserve with Diabetic Retinopathy in Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2014 Jun;57(6):1124-31. doi: 10.1007/s00125-014-3199-7. Epub 2014 Mar 6, Diabetologia, 2014 Jun;57(6):1124-31, 218-25, 2014
  • Jenkins, A.J., Fu, D., Azar, M., Stoner, J.A., Kaufman, D.G., Zhang, S.X., Klein, R.L., Lopes-Virella, M.F., Ma, J.X.& Lyons, T.J.and the VADT Study Group (includes R.J. Anderson as site PI) Clinical Correlates of Serum Pigment Epithelium-Derived Factor in Type 2 Diabetes Patients. J Diabetes Complications. 2014 May-Jun;28(3):353-9. doi: 10.1016/j.jdiacomp.2014.01.008. Epub 2014 Jan 17., Journal of Diabetes and Its Complications, 2014 May-Jun;28(3), 353-9, 2014
  • Shah, K., Anderson, R.J.: Adrenal insufficiency as the presenting manifestation of small cell lung carcinoma metastatic to the infundibulum and pituitary. BMJ Case Reports 2014; doi:10.1136/bcr-2013-203224 (PMID#24532238)., BMJ Case Report, 2014 Feb 14;2014, 2014
  • Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, McCarren M, Reaven P, Hayward R, Duckworth W andthe VADT Study Group (includes R.J. Anderson as site PI). Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT) Diabetes Care, 2014 Feb; 37 (2) 501-6., Diabetes Care, 2014 Feb; 37 (2) , 501-6, 2014
  • Mark B Zimering, Robert J Anderson, Ling Ge, Thomas E Moritz, William C Duckworth, for the VADT Study Investigators (includes R.J. Anderson as site PI). Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the Veterans Affairs Diabetes Trial. Front Endocrinol, 2013 Nov 22. doi: 10.3389/fendo.2013.00183. (PMID: 24319441), Front. Endocrinol., 2013 Nov 22;4, 183, 2013
  • Fried, L.F., Emanuele, N., Zhang, J.H. et al. for the VA NEPHRON-D Investigators (includes R.J. Anderson, M.D.), Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. November 9, 2013. DOi:10.1056/NEJMoa1303154., New England Journal of Medicine, November 9, 2013, 1892-903, 2013
  • Scirica,B.M., Bhatt, D.L., Braunwald, E, et al. and the SAVOR-TIMI 53 Investigators (includes R.J. Anderson as site PI) Saxagliptin and cardiovascularoutcomes in patients with Type 2 diabetes mellitus. N. Engl. J. Med. 2013. DOi:10.1056/NEJMoa1307684., New England Journal of Medicine, 2013 Oct 3;369(14), 1317-26, 2013
  • Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD for the VADT Investigators (includes R.J. Anderson as site PI). The Effect of IntensiveGlucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2013 published ahead of print March 27, 2013, doi:10.2337/dc12-2082., Diabetes Care, 2013 Aug;36(8), 2408-14, 2013
  • Madona Azar, Timothy J. Lyons, Petar Alaupovic, Julie A. Stoner, Carmen Quiroga, Derrick G. Kaufman, Maria Lopes-Virella, Richard L. Klein, Alicia J. Jenkins, VADT Study Group (includes R.J. Anderson as site PI). Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Aug 1. doi:pii: S1056-8727(13)00113-X. 10.1016/j.jdiacomp.2013.05.005. [Epub ahead of print], Journal of Diabetes and Its Complications, 2013 Nov-Dec;27(6), 627-32, 2013
  • Mark B. Zimering, Thomas E. Moritz, Robert J. Donnelly for the VADT Study Group (includes R.J. Anderson as site PI). Anti-Neurotrophic Effects from Autoantibodies in Adult Diabetes Having Primary Open Angle Glaucoma or Dementia. Front Endocrinol (Lausanne). 2013; 4: 58., Front. Endocrinol., 2013; 4, 58, 2013
  • Zinman, B., Kahn, S.E., Haffner, S.M., O’Neill, M.C., Heise, M.A., Freed, M.I. for the ADOPT Study Group (includes R.J.Anderson): Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with Type 2 diabetes in North America and Europe., Diabetes, 53, 3193-3200, 2004
  • Ebmeier, C.C. and Anderson, R.J.: Human thyroid phenol sulfotransferases SULT1A1 and SULT1A3: Activities in normal and diseased thyroid glands, and inhibition by thyroid hormones and phytoestrogens., J. Clin Endo. and Metab., 89, 5597-5605, 2004
  • Anderson, R. and Ebmeier, C.: Human anterior pituitary sulfotransferase SULT1A1 and SULT1A3 activities., 12 International Congress of Endocrinology Proceedings, Lisbon, Portugal, 1197-1201, 2004
  • Shah, J., Kirkman, S., Wendel, C., McCarren, M., Duckworth, W., Abraira, C. and the VADT group (includes R.J. Anderson). Baseline Macrovascular Disease Correlates in Older Type 2 Diabetic Patients in US Veterans Affairs Diabetes Trial (VADT)., 12 International Congress of Endocrinology Proceedings, Lisbon, Portugal, 653-658, 2004
  • Abraira, C., Sacks, J., Emanuele, N., Klein, R., Duckworth,W., and the VADT Group (includes R.J. Anderson). Retinopathy Associations in the V.A. Diabetes Trial., 12 International Congress of Endocrinology Proceedings, Lisbon, Portugal, 435-439, 2004
  • Reaven, P.D., Sacks, J. and VADT investigators (includes R.J. Anderson). Reduced Coronary and abdominal Artery Calcification in Hispanics with type 2 Diabetes., Diabetes Care, 27, 1115-1120, 2004
  • Anderson, R.J.: Adrenal Hirsutism/Virilization, Adrenal Section, ASAP (AACE Self Assessment Profile in Endocrinology and Metabolism) Syllabus, 2003-2004, In Press, 2004
  • McKenney, J.M., Jones, P.H., Adamczyk, M.A., Cain, V.A., Bryzinski, B.S., Blasetto, J.W. for the STELLAR Study Group (includes R.J. Anderson): Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial., Current Medical Research and Opinion, 19, 689-698, 2003
  • Abraira, C., Duckworth, W., McCarren, M., Emanuele, N., Arca, D., Reda, D., Henderson, W. for the participants of the VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2 (includes RJ Anderson): Design of the Cooperative Study on Glycemic Control and Complications in Diabetes Mellitus Type 2: Veterans Affairs Diabetes Trial (VADT)., Journal of Diabetes and Its Complications, 17, 314-322, 2003
  • Jones, P.H., Davidson, M.H., Stein, E.A. et al, for the STELLAR Study Group (includes R.J. Anderson): Comparison of the efficiacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)., American Journal of Cardiology, 92, 152-160, 2003
  • Anderson, R.J.: Adrenal Hirsutism/Virilization, Adrenal Section for the ASAP (AACE Self Assessment Profile in Endocrinology and Metabolism) 2003-4 Syllabus, Not Applicable, In Press, 2003
  • Ibert C. Wells, John P. Classen, and Robert J. Anderson; A test for adequacy of chromium nutrition in humans-relation to Type 2 diabetes ,ellitus., Biochem. Biophys. Res. Commun., 303, 825-827, 2003
  • Abraira, C., Duckworth, W., McCarren, M., Emanuele, N., Arca, D., Reda, D., Henderson, W. for the participants of the VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2 (includes RJ Anderson): Design of the Cooperative Study on Glycemic Control and Complications in Diabetes Mellitus Type 2: Veterans Affairs Diabetes Trial (VADT)., J. Diabetes and Its Complications, In Press, 2003
  • Freed, M.I., Ratner, R., Marcovina, S.M., Kreider, M.M., Biswas, N., Cohen, B., Brunzell, J.D. and the Rosiglitazone Study 108 Investigators (includes R.J. Anderson): Effects of Rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus., American Journal of Cardiology, 90, 947-952, 2002
  • Hartman, M.L., Crowe, B.J, Biller, B.M.K., Ho, K.Y., Clemmons, D.R., Chipman, J.J. and The HypoCCS Advisory Board and The U.S. HypoCCS Study Group (includes R.J. Anderson): Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?, Journal of Clinical Endocrinology and Metabolism, 87, 477-485, 2002
  • Li, X-Y, Clemens, D.L., Cole, J.R. and Anderson, R.J.: Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate., J. Endocrinol., 171(#3), 525-532, 2001
  • Lewis, E.J., Hunsicker, L.G., Clarke, W.C., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., and Raz, I. for the Collaborative Study Group (includes R.J. Anderson): Renoprotective effect of the angiotensin-receptor anatgonist irbesartan in patients with nephropathy due to Type 2 diabetes., New England Journal of Medicine, 345, 851-860, 2001
  • Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI for the Rosiglitazone Clinical Trials Group (includes RJ Anderson). Rosiglitazone monotherapy is effective in patients with Type 2 diabetes., J Clin Endocrinol Metab, 86:, 280-288, 2001
  • Anderson RJ: Adrenal hirsutism/virilization, Adrenal Section of the 2000 Syllabus., ASAP (AACE Self Assessment Profile in Endocrinology and Metabolism) Syllabus, 17-25, 2001
  • Dubin RL, Hall CM, Pileri CL, Kudlacek PE, Yee JA, Li X-Y, Johnson ML, Anderson RJ. Thermostable (SULTIA1) and thermolabile (SULTIA3) phenol sulfotransfereases in human osteosarcoma and osteoblast cells., Bone, 28:, 617-624, 2001
  • Rosenstock J,Schwartz SL, Clark CM, Park GD, Conley DW, Edwards MN (for the 3006 Study Group, including RJ Anderson). Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin., Diabetes Care, 24:, 631-636, 2001
  • Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Lewis EJ for the Collaborative Study Group (includes RJ Anderson). The irbesartan type II diabetic nephropathy trail: Study design and baseline characteristics., Nephrol Dial Transplant, 15:, 487-497, 2000
  • White KE and Bilous RW for the Collaborative Study Group IDNT (Includes RJ Anderson). Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to Type 1 diabetes., J Am Soc Nephrol, 11:, 1667-1673, 2000
  • Li X, Clemens DL, Anderson RJ: Sulfation of iodothyronines by recombinant human sulfotransferase SULTICI., Biochem Pharmacol, 60:, 1713-1716, 2000
  • Thrailkill, K.M., Quattrin, T., Baker, L., Kuntze, J.E., Compton, P.G., Martha, P..M. for the rhIGF-I in IDDM Study Group (includes R. J. Anderson): Cotherapy with recombinant human insulin-like growth factor-I and insulin improves glycemic control in Type 1 diabetes Diabetes Care 22: 585-592, 1999, Not Applicable, 1999
  • Patel, J., Anderson, R.J., Rappaport, E.B.: Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: A 12-week, randomized placebo-controlled study. Diabetes, Obesity & Metabolism, 1:165-172, 1999, Not Applicable, 1999
  • Li, Xinying and Anderson, R.J.: Sulfation of iodothyronines by recombinant human liver steroid sulfotransferases. Biochem. Biophys. Res. Comm. 263:632-639, 1999., Not Applicable, 1999
  • 4.Anderson, R.J.: ”Hypopituitarism.” In: Conn's Current Therapy, 2000, Ed, R.E. Rakel, pp. 635-640, Philadelphia, W.B. Saunders Company, 2000., Not Applicable, 1999
  • Anderson, R.J.: Adrenal Hirsutism/Virilization, Adrenal Section for the ASAP (AACE Self Assessment Profile in Endocrinology and Metabolism) 2003-4 Syllabus, submitted, February, 2002.
  • Wells, I.C., Claassen, J.P. and Anderson, R.J.: A test for adequacy of chromium nutrition in humans- Relation to Type 2 diabetes mellitus. Submitted, Biochem. Biophys. Res. Comm., 2002.
  • Wells, I.C.and Anderson, R.J.: Involvement of magnesium in the etiology of Type 2 diabetes mellitus. Submitted to Diabetes, 2002.

Publications

  • Shah KK, Tarasova V, Anderson RJ:.A Case of a Functioning Extra-Adrenal Retroperitoneal Composite Paraganglioma and Ganglioneuroma. Endocrine Practice 22 (Supplement 1):24, 2016 (May). Presented May 27, 2016 AACE 25th Annual Meeting (Abst #142), Orlando, FL,., Abst #142, 2016
  • Nguyen, A-T, Khanal, N., Lambrecht, J.E., Anderson, R.J.: Refractory Hypothyroidism Due to L-Thyroxine Malabsorption. Endocrine Practice 22 (Supplement 1):301, 2016 (May). Presented May 27, 2016 AACE 25th Annual Meeting (Abst #1196), Orlando, FL., Abst #1196, 2016
  • Yousefian, S., Anderson, R.J.: Cushing's Disease Identified Post-Adrenalectomy for Adrenal Nodules. Endocrine Practice 22 (Supplement 1):215, 2016 (May). Presented May 27, 2016 AACE 25th Annual Meeting (Abst #939), Orlando, FL., Abst #939, 2016
  • Tarasova V.D., Shah K.K, White, M., Anderson, R.J, Armas, L.G.A.: Physiological Response of Cortisol to Cardiac Catheterization. Accepted for presentation at the ENDO2015, SAT-400, March 7, 2015., Endocrine, 2015
  • Saiprasad, S., Gallagher, J.C., Anderson, R.J.: Chronic Functional Hypoparathyroidism due to Magnesium Deficiency. Accepted for presentation at the ENDO2015, SAT-203, March 7, 2015., Endocrine, 2015
  • Shah, K.K., Joven, M., Tarasova, V., Saiprasad, S., Flor, S., Anderson, R.J. Anterior pituitary dysfunction in military Veterans with mild Traumatic Brain Injury (mTBI): A pilot study. Accepted for presentation at the 14th International Pituitary Congress. March 3-4, 2015, Endocrine, 2015
  • Shah, K.K., Tarasova, V.D., Davidian, M., Anderson, R.J.: Painful acute radiation thyroiditis induced by 131I treatment of Graves’ disease. ICE/ENDO2014, SAT- 0523, June 21, 2014., Endocrine, 2014
  • Shah, K.K., Anderson, R.J.: Therapeutic benefits of growth hormone replacement therapy in growth hormone deficient patients following traumatic brain injury: a systematic review. ICE/ENDO2014, SAT-0731, June 21, 2014., Endocrine, 2014
  • Joven, M., Anderson, R.J.: Follicular thyroid cancer presenting as a hot nodule and subclinical hyperthyroidism. ICE/ENDO2014, SAT-0493, June 21, 2014., Endocrine, 2014
  • Tarasova, V.D., Nahar, N., Dietz, N.E., Recker, R.R., Anderson, R.J.: Unique Occurrence and Course of Graves’ Disease in a Patient with PTEN Hamartoma Tumor Syndrome. THYROID 23.No.S1,A-66 (Poster #150). American Thyroid Association 83rd Ann Meeting, San Juan Puerto Rico, October 16-20, 2013,, Other, 2013
  • Tarasova, V.D., Kolukula, S., Anderson, R.J.: A novel mutation of thyroid hormone receptor Beta subunit causing resistance to thyroid hormone. THYROID 23.No.S1,A-76 (Poster #177).American Thyroid Association 83rd Ann Meeting, San Juan Puerto Rico, October 16-20, 2013., Other, 2013
  • Anderson, R.J., Bahn, G., Emanuele, N. Marks, J., Duckworth, W.: Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes 62:Supplement 1; Late Breaking Abstracts:2013-LB-5755-Diabetes, July 2013., Diabetes, 2014 Oct;37(10), 2782-8, 2013
  • Olin, J.R., Ebmeier, C.C., Anderson, R.J.: Human premenopausal and postmenopausal liver steroid sulfotransferase (SULT) activities with tibolone metabolites., ENDO2005, Endocrine Society Mtg, (P2-304) 430, 2005
  • Ebmeier, C.C., Olin, J.R., Anderson, R.J.: Sulfation of tibolone metabolites by postmenopausal human liver produces predominantly monosulfated compounds., ENDO2005, Endocrine Society Mtg, P2-305) 430, 2005
  • Emanuele, N., Sacks, J., Klein, R., Duckworth W, Abraira C., and the Veterans Affairs Diabetes Trial (VADT) group (includes RJ Anderson). Ethnicity and other retinopathy correlations of baseline photographs in the VA Diabetes Trial. New Orleans, LA., Diabetes, 53, 2004
  • Kirkman, M.S., McCarren, M., , Abraira C., Duckworth W., and the VADT study group (includes R.J. Anderson). Cardiovascular disease correlates with traditional risk factors but not with glycemic control in established Type 2 diabetes. New Orleans, LA, Diabetes, 53:S2, A77, 2004
  • Zimering, M.B., Sacks, J. and the VADT study group (includes R.J. Anderson). Plasma basic fibroblast growth factor (bFGF) increases with degree of abdominal obesity in patients with Ytype 2 diabetes mellitus enrolled in the Veterans Affairs Diabetes Trial (VADT). Boston, MA, Not Applicable, In Press, 2004
  • Wang, M. and Anderson, R.J.: Sulfation of tibolone metabolites by postmenopausal human liver sulfotransferase activities. 2004 Experimental Biology meeting abstracts [on CD-ROM]., FASEB Journal, 18, 646.9, 2004
  • Ebmeier, C. and Anderson, R.J.: Phytoestrogen sulfation by human thyroid phenol sulfotransferases (SULTs): Inhibition of the SULT activities by daidzein and genistein. 2004 Experimental Biology meeting abstracts [on CD-ROM]., FASEB Journal, 18, 793.9, 2004
  • Abraira C, Duckworth W, McCarren M, Shah J, Anderson R and the Veterans Affairs Diabetes Trial (VADT) group. Cardiovascular (CV) risk factors in the Veterans Affairs Diabetes Trial (VADT)., Diabetes and Metabolism, 29 (4S), 341, 2003
  • Anderson R, Duckworth W, Abraira C, McCarren M, Shah J and the Veterans Affairs Diabetes Trial (VADT) group. Design and baseline characteristics of the VADT: The effects of glucose control on cardiovascular outcomes in Type 2 diabetes., Diabetes and Metabolism, 29 (4S), 341, 2003
  • Abraira, C., Duckworth, W.C., McCarren, M., Shah,J., Anderson, R.J., and the VADT Investigators: Cardiovascular (CV) risk factors in the Veterans Affairs Diabetes Trial (VADT). 18th IDF Congress, In Press, 2003., Not Applicable, 2003
  • Herman, W., Freed, M.I., Heise, M., Kravitz, B., Perry, A., and the ADOPT Study Group (includes R.J. Anderson): The ADOPT Study: symptoms and health status in a recently-diagnosed type 2 diabetic population(Abs.#1130). In Press 63rd Scientific Sessions of the ADA, New Orleans, LA, June 13-17, 2003., Not Applicable, 2003
  • Haffner, S.M., Zinman, B., Kahn, S.E., Herman, W.H., Heise, M.A., O’Neill, M.C., Porter, L.E., and the ADOPT Study Group (includes R.J. Anderson): Ethnic differences in the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetes in North America (Abs.#945). 63rd Scientific Sessions of the ADA, New Orleans, LA, June 13-17, 2003., Not Applicable, 2003
  • Kahn, S.E., Haffner, S.M., Zinman, B., Heise, M.A., O’Neill, M.C., Porter, L.E., and the ADOPT Study Group (includes R.J. Anderson): Lack of concordance of NCEP and WHO criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe (Abs.#952). 63rd Scientific Sessions of the ADA, New Orleans, LA, June 13-17, 2003., Not Applicable, 2003
  • Zinman, B., Kahn, S.E., Haffner, S.M., Herman, W.H., Heise, M.A., O’Neill, M.C., and the ADOPT Study Group (includes R.J. Anderson): Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes: The ADOPT Study Cohort (Abs.#999). 63rd Scientific Sessions of the ADA, New Orleans, LA, June 13-17, 2003., Not Applicable, 2003
  • Viberti, G.C., Freed, M.I., Holman, R., Lachin, J., Heise, M., and the ADOPT Study Group (includes R.J. Anderson): Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT Study (Abs.#817). 63rd Scientific Sessions of the ADA, New Orleans, LA, June 13-17, 2003., Not Applicable, 2003
  • Anderson, R.J., Duckworth, W.C., Abraira, C., McCarren, M., Shah,J., and the VADT Investigators: Design and baseline characteristics of the Veterans Affairs Diabetes Trial (VADT): the effect of glucose control on cardiovascular (CV) outcomes in Type 2 diabetes. 18th IDF Congress, In Press, 2003., Not Applicable, 2003
  • Anderson, R.J., Abraira, C., Duckworth, W.C., McCarren, M., Zimering, M.B., and the VADT Trial Group: Blood pressure control in the Veterans Affairs Diabetes Trial (VADT). The Endocrine Society 85th Annual Meeting, In Press, 2003., Not Applicable, 2003
  • Ebmeier, C.C., Anderson, R.J.: Human Thyroid Phenol Sulfotransferases (SULT1A1 and SULT1A3): Biochemcial Properties and Activities in Normal and Diseased Thyroids. The Endocrine Society 85th Annual Meeting, In Press, 2003., Not Applicable, 2003
  • Middleton, J.P., Lewis, J., for the Collaborative Study Group – IDNT Study (includes RJ Anderson): Predictors of the progression of renal insufficiency in patients with type 2 diabetes and overt diabetic nephropathy. American Society of Nephrology Annual Scientific Meeting, Not Applicable, 2002
  • Atkins, R., Braden, G., Briganti, E., de Crespigny, P.J.C., DeFerrari, G., Drury, P., Hunsicker, L., Lewis, J., Locatelli, F., Wiegmann, T.B. for the Collaborative Study Group (includes RJ Anderson): Effect of baseline proteinuria and change in proteinuria on risk of renal endpoints in the IDNT. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002, Not Applicable, 2002
  • Rodby, R. Gilbert, R. for the Collaborative Study Group – IDNT Study (includes RJ Anderson): The presence of retinopathy is associated with poor renal and cardiovascular outcomes type 2 diabetic nephropathy. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002., Not Applicable, 2002
  • Pohl, M.A., Cordonnier, D.J., Spitalewitz, S. and the Collaborative Study Group – IDNT Study (includes RJ Anderson): Impact of angiotensin receptor blockade with irbesartan on renal function at different systolic blood pressure (SBP) levels in type 2 diabetic nephropathy. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002., Not Applicable, 2002
  • Weir, M.R., Hunsicker, L.G. for the Collaborative Study Group – IDNT Study (includes RJ Anderson): The severity of orthostatic hypotension is a risk factor in the progression of type 2 diabetic nephropathy. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002., Not Applicable, 2002
  • Pohl, M.A., Blumenthal, S., Hunsicker, L.G. and the Collaborative Study Group – IDNT Study (includes RJ Anderson): Impact of achieved systolic blood pressure on the renal function in type 2 diabetic nephropathy. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002., Not Applicable, 2002
  • Berl, T., for the Collaborative Study Group (includes RJ Anderson): Cardiovascular outcomes in the irbesartan diabetic nephropathy trial (IDNT) of patients with type 2 diabetes and overt nephropathy. American Society of Nephrology Annual Scientific Meeting, November 1-5, 2002., Not Applicable, 2002
  • Anderson, R.J., Kudlacek, P.E., Li, X-Y,: Thermostable phenol sulfotransferase (SULT1A1) is present in COS-1cells and catalyzes the sulfation of 3,3’-diiodothyronine. (28th Annual Meeting of the European Thyroid Association, Goteborg, Sweden, September 7-11, 2002); Journal of Endocrinological Investigation 25: (Suppl to No.7), 59, 2002., Not Applicable, 2002
  • Hardin, K.N., Kudlacek, P.E., Li, X-Y, Anderson, R.J.: Thermostable phenol sulfotransferase (SULT1A1) is present in SV40 transformed African green monkey kidney cells (COS-1). Proceedings of the Southwestern and Rocky Mountain Division AAAS-SWARM, 3rd Annual Midwest Meeting (Omaha, NE, Nov. 11-13) 41 (#2):18, 2001., Not Applicable, 2001
  • Li, X-Y, Clemens, D., Anderson, R.: Specificities of human hydroxysteroid sulfotransferase 2B1a (SULT2B1a) and mutant SULT2B1a enzymes for thyroid hormones and dehydroepiandrosterone (DHEA). Washington, D.C., Not Applicable, 2001
  • Sype, J.W. and Anderson, R.J. : A case of long-standing hyponatremia and hypothyroidism associated with an incidentally discovered pituitary macroadenoma, October, 2001, Abstract Book, ACP-ASIM, Nebraska Chapter Meeting Proceedings,, In Press, 2001
  • Abraira C, Duckworth W, McCarren M and the VADT Study Group (includes RJ Anderson): The Veterans Affairs Type 2 Diabetes Trial (VADT). Denver, CO, ENDO2001, Endocrine Society Mtg, 2001
  • Li-X-Y, Clemens DL, Anderson RJ: Alteration of human hydroxysteroid sulfotranferase 2B1a (SULT2B1a) substrate affinities by mutation of amino acid residues., Omaha, NE, Soc Mol Biol Genet, #15, 2001
  • Lewis EJ, Hunsicker LG, Clarke WC for the Collaborative Study Group (includes RJ Anderson): A clinical trial in patients with overt type 2 diabetic nephropathy., American Society of Hypertension, 2001
  • Anderson RJ, Li X-Y, Clemens D: Sulfation of thyroid hormones by multiple human recrombinant cytosolic sulfotransferases (SULTs), ICE (International Congress of Endocriniology) 2000 Abstracts, 277, 2000
  • Li X-Y, Anderson R: Human liver recombinant thermostablel phenol sulfotransferase (SULTIA1) allozymes characterized with iodothyronines., FASEB Journal, 14:, A1446, 2000
  • Kudlacek, P., Clemens, D., Anderson, R.: Human liver recombinant thermostable phenol sulfotransferase (SULT1A1) allozymes characterized with minoxidil. FASEB J. 13(#5):A1013, 1999, Not Applicable, 1999
  • Kudlacek, P., Clemens, D., Anderson, R.: Human liver recombinant thermostable phenol sulfotransferase (SULT1A1) allozymes characterized with minoxidil. J. Invest. Med. 47:197A, 1999, Not Applicable, 1999
  • Li, X.-Y. and Anderson, R.: Sulfation of triiodothyronine by recombinant human liver steroid sulfotransferases. FASEB J. 13(#5):A813, 1999, Not Applicable, 1999
  • Li, X.-Y. and Anderson, R.: Sulfation of triiodothyronine by recombinant human liver steroid sulfotransferases . J. Invest. Med. 47:199A, 1999, Not Applicable, 1999
  • Hartman, M., Crowe, B., Chipman, J., for the HypoCCS Investigator Group (includes R.J. Anderson): Baseline characteristics of adults with GH deficiency (GHD): comparison of patients who receive GH replacement therapy with those not treated. Program of the 6th International Pituitary Congress, p.61, Long Beach, CA, June 15-17, 1999, Not Applicable, 1999
  • Rosenstock, J., Schwartz, S., Clark, C., Edwards, M., Donley, D. (Protocol 3006 Study Group includes R. Anderson): Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insulin-controlled trial. Diabetes 48: (Suppl. 1):A100, 1999, Not Applicable, 1999
  • Kudlacek, P., Anderson, R.: Altered biochemical properties of recombinant human liver chimeric sulfotransferases (SULT). Proceedings of the Southwestern and Rocky Mountain Division AAAS, 1st Midwest Regional Meeting (Omaha, NE, October 31- November 2) 39 (#2):24, 1999, Not Applicable, 1999
  • Li, X.-Y., Clemens, D., Anderson, R.: Thyroid hormone sulfation by recombinant human sulfotransferase SULT1C1. Proceedings of the Southwestern and Rocky Mountain Division AAAS, 1st Midwest Regional Meeting (Omaha, NE, October 31- November 2) 39 (#2):25, 1999., Not Applicable, 1999

Presentations

  • Faculty Speaker, “Traumatic Brain Injury and Endocrine Dysfunction in Veterans,” Creighton Department of Medicine Grand Rounds, Omaha, NE, December 16, 2015., 2015
  • Speaker, “Thyroid Nodules" Medicine Resident Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, October 23, 2015, 2015
  • Speaker, “Thyroid Update" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, July 7, 2015, 2015
  • Speaker, “Mild Traumatic Brain Injury and Pituitary Dysfunction: Update,” Creighton Department of Medicine Research Conference, Omaha, NE, May 14, 2015, 2015
  • Speaker, “Pheochromocytoma,” Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, May 12, 2015., 2015
  • Speaker, Pituitary Board Reviews, Internal Medicine Board Review Lectures, CUMC, May 11, 2015., 2015
  • Faculty Moderator “Adrenal 2,” Department of Medicine Reisdent Core Lectures, April 6, 2015., 2015
  • Faculty Moderator “Adrenal 1,” Department of Medicine Resident Core Lectures, March 30, 2015., 2015
  • Faculty Moderator “Thyroid,” Department of Medicine Reisdent Core Lectures, March 23, 2015., 2015
  • M2 Introduction to Clinical Medicine (1 hour), “Adrenal,” CUSM, January 27, 2015., 2015
  • M2 Introduction to Clinical Medicine (1 hour), “Hypothalamic-Pituitary Function and Disease,” CUSM, January 26, 2015., 2015
  • Speaker, “Cushing’s Update" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, January 20, 2015., 2015
  • Board Reviews; Endocrine Fellows, November 25, 2014., 2014
  • Speaker, “Mild Traumatic Brain Injury and Pituitary Dysfunction,” Creighton Department of Medicine Research Conference, Omaha, NE, October 9, 2014., 2014
  • Speaker, “Cushing’s" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, September 16, 2014., 2014
  • Speaker, “Thyroid Physiology" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, July 22, 2014,., 2014
  • Invited speaker, “Endocrine Emergencies,” Acute Care Core Curriculum Series, Department of Medicine, Omaha, NE, July 2, 2014., 2014
  • Speaker, “Genetic screening and counseling in endocrine metabolic diseases,” Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, July 1, 2014., 2014
  • Speaker, Thyroid Board Reviews, Internal Medicine Board Review Lectures, CUMC, June 2, 2014., 2014
  • Speaker, “Acromegaly" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, May 27, 2014., 2014
  • Speaker, “Pheochromocytoma,” Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, February 18, 2014., 2014
  • Invited Speaker, DKA and HHS Treatment Approaches with Insulin Infusion,” Pulmonary and Critical Medicine Conference, CUMC, Omaha, NE, February 7, 2014., 2014
  • M2 Introduction to Clinical Medicine (1 hour), “Adrenal,” CUSM, January 28, 2014., 2014
  • M2 Introduction to Clinical Medicine (1 hour), “Hypothalamic-Pituitary Function and Disease,” CUSM, January 27, 2014., 2014
  • Speaker, “VA-NEPHRON-D: End of combination therapy for diabetic Nephropathy?” Department of Medicine Grand Rounds, CUMC, December 18, 2013., 2013
  • Speaker, "Thyroid Ultrasound and FNA Applications." Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, December 17, 2013., 2013
  • Invited Speaker, “Veterans Affairs Diabetes Trial (VADT) and Renal Outcomes,” Research Conference, Department of Medicine, Omaha, NE, November 14, 2013., 2013
  • Speaker, “Diabetic Emergencies: DKA and HHS,” Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, November 12, 2013., 2013
  • Speaker, “Mild Traumatic Brain Injury and Pituitary Dysfunction,” Creighton Osteoporosis Research Center Friday Conference, Omaha, NE, November 8, 2013., 2013
  • Speaker, “Cushing’s" Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, September 24, 2013., 2013
  • Invited speaker, “Endocrine Emergencies,” Acute Care Core Curriculum Series, Department of Medicine, Omaha, NE, August 8, 2013., 2013
  • Speaker, “Hypothyroidism Update,” Endocrine Fellowship Core Series, Department of Medicine, Division of Endocrinology, Omaha, NE, July 30, 2013, 2013
  • Guest Speaker, Metabolism of tibolone metabolites in human tissues, Advisory Meeting, San Diego, CA, 2005
  • Invited speaker, “Internal Medicine Board Reviews-Endocrinology (1.5 hours),”, 2005
  • Invited Speaker, “Antithyroid Drugs,” Morning Report, Department of Medicine, VAMC, 2005
  • Guest Speaker (Funded), “Sulfation of Tibolone Metabolites by Human Postmenopausal Tissues,” Tibolone Metabolism Symposium, Philadelphia, PA, March 31, 2005., 2005
  • Invited Speaker, “Hypogonadism,” Morning Report, Department of Medicine, VAMC, 2005
  • Invited Speaker, “Thyroid Nodules,” Morning Report, Department of Medicine, VAMC, 2005
  • Invited Speaker, “Initiation of Insulin in Diabetes Mellitus,” Morning Report, Department of Medicine, VAMC, 2004
  • Invited Speaker, “Subclinical Thyroid Disease,” Morning Report, Department of Medicine, VAMC, 2004
  • Invited speaker, “Endocrine Emergencies,” Acute Care Core Curriculum Series, Department of Medicine, Omaha, NE,, 2004
  • Invited Speaker (Funded), “Metabolic Syndrome,” Council Bluffs, IA, June 17, 2004., 2004
  • Oral Presentation-Ebmeier, C. and Anderson, R.J.: Phytoestrogen sulfation by human thyroid phenol sulfotransferases (SULTs): Inhibition of the SULT activities by daidzein and genistein. EB(Experimental Biology)2004 International Meeting, Washington, DC, 2004
  • Wang, M. and Anderson, R.J.: Sulfation of tibolone metabolites by postmenopausal human liver sulfotransferase activities. EB (Experimental Biology) Poster Presentation, 2004
  • "Maintaining HbA1c Separation in the Long-term VADT Study." VA Diabetes Trial (VADT) COOP Study #465 Investigators’ Meeting, Chicago, IL, 2004
  • Invited speaker, “Nazi Doctors” Grand Rounds, Omaha, NE, March 24, 2004., 2004
  • Invited speaker, Treatment of Thyroid Diseases, Family Practice Lecture Series, Omaha, NE, 2004
  • Invited Speaker, “Treatment Strategies in the VA Diabetes Trial,” VA Staff Physician Conference, Lincoln VAMC, Lincoln, NE, 2003
  • Invited Speaker (Funded), “Diabetic Dyslipidemia: Treatment Update,” Marshalltown Iowa Medicial Staff Meeting, 2003
  • Invited speaker, “Endocrine Emergencies,” Acute Care Core Curriculum Series, Department of Medicine, Omaha, NE, 2003
  • Guest Symposium Speaker, “Blood pressure control in the VA Diabetes Trial (VADT),” Clinical Trials Symposium, Endocrine Society 2003, Philadelphia, PA, 2003
  • Blood pressure control in the Veterans Affairs Diabetes Trial (VADT), 2003
  • Thyroid Hormone Metabolism:reSULTs and inSULTs. Creighton University Department of Medicine Research Conference, 2003
  • Speaker, "Hormones for Aging Men: HRT Deja Vu?" Creighton University School of Medicine Grand Rounds, 2003
  • Invited Speaker, “Choosing Appropriate Patients for Weight Loss,” Morning Report, Department of Medicine, VAMC., 2003
  • Rsearch in Type 2 Diabetes at the VA, 2003
  • Invited Speaker, “Hyperglycemia in Acutely Ill Patients,” Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker, “Subclinical Thyroid Disease,” Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker amd Moderator (Funded), “Diabetes Treatment Programs:CADRE,” Ironwood Golf Club, Omaha Nebraska, November 2, 2002., 2002
  • Invited Speaker (Funded), “Managing Methods and Strategies for ATP III Goal Attainment: Conquering the New Treatment Frontier,” Nick and Tony’s, Omaha, Nebraska., 2002
  • Invited Speaker, “Drugs for treatment of Diabetes- An Update,” Nursing Inservice, Ambulatory Care, VAMC, October 18, 2002., 2002
  • Invited Speaker, “HDL Cholesterol as a risk factor,” Morning Report, Department of Medicine, VAMC, October 10, 2002., 2002
  • Invited speaker, “Hospital Control of Diabetes Mellitus- discussant panel,” Creighton University Department of Medicine Grand Rounds, Omaha, NE., 2002
  • Invited Speaker, “Prevention of Diabetes Mellitus,” Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker, “Classification of Diabetes Mellitus,” Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker (Funded), “Metabolic Syndrome: A Tale of the Tape-Treatment Options,” The French Café, Omaha Nebraska, 2002
  • Department of Medicine, “Endocrine Board Review Session” 2 hours, 2002
  • “Recent Classification of Diabetes Mellitus,” Morning Report, Department of Medicine, VAMC, 2002
  • “Diabetic Nephropathy,” Morning Report, Department of Medicine, VAMC, 2002
  • Department of Medicine Grand Rounds, “Some Endocrine Nutraceuticals: What are we to do?”, 2002
  • “Hospital-Based Diabetes Treatment,” Morning Report, Department of Medicine, VAMC, 2002
  • “Hypertension in Diabetes,” Morning Report, Department of Medicine, VAMC, 2002
  • Invited speaker, "Pituitary Apoplexy," Department of Medicine Morning Report, Omaha, NE., 2002
  • Invited Speaker, "Nodular Thyroid Disease," Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker (Funded), "Optimizing Lipid Lowering: Utilizing the Most Recent Therapies in Getting Patients to Goal," The French Café, Omaha Nebraska., 2002
  • Invited Speaker, "Metabolic Syndrome," Morning Report, Department of Medicine, VAMC., 2002
  • Invited Speaker, "Adrenal insufficiency," Morning Report, Department of Medicine, VAMC., 2001
  • Hardin, K.N., Kudlacek, P.E., Li, X-Y, Anderson, R.J.: Thermostable phenol sulfotransferase (SULT1A1) is present in SV40 transformed African green monkey kidney cells (COS-1). Proceedings of the Southwestern and Rocky Mountain Division AAAS-SWARM, 3rd Annual Midwest Meeting (Omaha, NE, Nov. 11-13) 41 (#2):18, 2001., 2001
  • Invited Speaker, "Drugs that cause hyperglycemia," Morning Report, Department of Medicine, VAMC., 2001
  • Invited Speaker, "Diagnosis of Diabetes," Morning Report, Department of Medicine, VAMC., 2001
  • Sype, J.W. and Anderson, R.J. : A case of long-standing hyponatremia and hypothyroidism associated with an incidentally discovered pituitary macroadenoma, ACP-ASIM, Nebraska Chapter Meeting Proceedings,, 2001
  • Invited Speaker, "Hyperthyroidism," Morning Report, Department of Medicine, VAMC., 2001
  • Invited Speaker, "Cholesterol Guideline Update," Morning Report, Department of Medicine, VAMC., 2001
  • Invited speaker, "Endocrine Emergencies," Department of Medicine, Omaha, NE,, 2001
  • Invited speaker, "Thyrotoxicosis," Department of Medicine Morning Report, Omaha, NE., 2001
  • "ADA Recognized Diabetes Outpatient Program", VAMC, Omaha, NE, 2001
  • "VISN 14 Diabetes Guidelines", VAMC, Omaha, NE, 2000
  • "Hypopituitarism" University of Santo Tomas School of Medicine and Surgery, Manila, Philippines, 2000
  • Anderson RJ, Li X-Y, Clemens D: Sulfation of thyroid hormones by multiple human recrombinant cytosolic sulfotransferases (SULTs). Presentation at the International Congress of Endocrinology, Sydney, Australia, 2000
  • "VISN 14 Diabetes Guidelines", VAMC, Omaha, NE, 2000
  • "Thyroid Disease in Primary Care, Family Practice Lecture Series, Omaha, NE, 2000
  • "Oral agent therapy in Type 2 diabetes", VAMC Nurse Inservice, Omaha, NE, 2000
  • Kudlacek, P., Clemens, D., Anderson, R.: Human liver recombinant thermostable phenol sulfotransferase (SULT1A1) allozymes characterized with minoxidil. FASEB J. 13(#5):A1013, 1999, 1999
  • Li, X.-Y. and Anderson, R.: Sulfation of triiodothyronine by recombinant human liver steroid sulfotransferases. FASEB J. 13(#5):A813, 1999., 1999
  • Kudlacek, P., Anderson, R.: Altered biochemical properties of recombinant human liver chimeric sulfotransferases (SULT). Proceedings of the Southwestern and Rocky Mountain Division AAAS, 1st Midwest Regional Meeting (Omaha, NE, October 31- November 2) 39 (#2):24, 1999, 1999
  • Li, X.-Y., Clemens, D., Anderson, R.: Thyroid hormone sulfation by recombinant human sulfotransferase SULT1C1. Proceedings of the Southwestern and Rocky Mountain Division AAAS, 1st Midwest Regional Meeting (Omaha, NE, October 31- November 2) 39 (#2):25, 1999., 1999
  • Department of Medicine Grand Rounds, "Adult Male Hypogonadism," August 18, 1999., 1999
  • Invited (Funded) Commentator, "Side Effects and adverse events with adult growth hormone therapy," 3rd Annual International HypoCCS Meeting, Lido at Venice, Italy, April 17, 1999, 1999
  • Invited (Funded) Speaker, Robert Bolinger Annual Lecture, "Androgen replacement therapy for adult male hypogonadism: ART for ADAM," UKMC Departments of Medicine and Endocrinology, Kansas City, Kansas, April 7, 1999, 1999
  • Invited (Funded) Guest Lectureship, "Male Hypogonadism Case Discussions," Medical Education Dinner, UKMC Department of Endocrinology, Kansas City, MO, April 6, 1999, 1999
  • Invited (Funded) Guest Lectureship, "Androgen deficiency in the adult male: Diagnosis and Treatment," Medical Education Conference, Good Samaritan Hospital/ Health Systems, Kearney, NE, March 12, 1999., 1999
  • Invited Lecturer, "MEN Syndromes", UNMC Endocrinology Conference, UNMC and VA Medical Centers, Omaha, NE, January 12, 1999., 1999
  • Invited (Funded) Guest Lectureship, "When and how to treat the androgen deficient adult male", Department of Medicine Grand Rounds, Rose Medical Center, University of Colorado Health Sciences Center, Denver, CO, January 5, 1999., 1999

Awards and Honors

  • Performance Award- Special Contribution to the Department of Veterans Affairs Mission, 2001
  • Visiting Professor of Endocrinology to University of Santo Tomas School of Medicine and Surgery, Manila, Philippines, 2000
  • VA Merit Review Award;, 1999